Early detection of lung cancer
SEATTLE—VisionGate Inc. reported significant findings in three recent studies at the 18th annual World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. These studies reportedly demonstrate important applications of the LuCED Lung Test for detection and treatment of lung cancer and pre-cancerous bronchial dysplasia.
The results of these studies are said to demonstrate that VisionGate’s LuCED Lung Test—a non-invasive liquid biopsy sputum test—advances the lung cancer diagnostic and treatment fields in three areas: accurate detection of small tumors and pulmonary nodules; detection and treatment of pre-cancerous dysplasia; and detection of key lung cancer driver mutations.
According to the company, the new bronchial dysplasia detection data illustrates the convergence of VisionGate’s diagnostic and pharmaceutical capabilities.
“These results further demonstrate the power of VisionGate’s patented technology to dramatically improve early detection, play a role in identification of patients for targeted therapy, and be a leader in cancer chemoprevention,” said Dr. Alan Nelson, VisionGate’s founder and CEO. “Our data continues to prove that we are revolutionaries in the lung cancer disease area.”
The purpose of this study was to assess the sensitivity of the non-invasive LuCED lung test across a range of tumor sizes including smaller, early-stage tumors. Sputum samples from 82 biopsy-confirmed lung cancer cases were studied. The study results demonstrated that VisionGate’s technology reliably identifies abnormal cells regardless of tumor size. Importantly, the LuCED lung test maintained consistently high specificity while providing 94 percent sensitivity to lung cancer.